These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7675374)

  • 1. Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
    Andolf E; Casslén B; Jörgensen C; Buchhave P; Lecander I
    Obstet Gynecol; 1995 Oct; 86(4 Pt 1):529-35. PubMed ID: 7675374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
    Casslén B; Bossmar T; Lecander I; Astedt B
    Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
    van Tilborg AA; Sweep FC; Geurts-Moespot AJ; Wetzels AM; de Waal RM; Westphal JR; Massuger LF
    Int J Oncol; 2014 Apr; 44(4):1394-400. PubMed ID: 24535412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
    Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
    Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activators in synovial fluid and plasma from patients with arthritis.
    Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
    Ann Rheum Dis; 1992 Aug; 51(8):965-8. PubMed ID: 1417121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
    Jänicke F; Schmitt M; Graeff H
    Semin Thromb Hemost; 1991 Jul; 17(3):303-12. PubMed ID: 1796300
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrinolytic components in fetal membranes and amniotic fluid.
    Watanabe T; Araki M; Mimuro J; Tamada T; Sakata Y
    Am J Obstet Gynecol; 1993 Apr; 168(4):1283-9. PubMed ID: 7682753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
    Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
    Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of criteria for the treatment of ovarian cysts on the bases of ultrasound and cytology.
    Matthes AC; Moreira de Andrade JM; Bighetti S
    Gynecol Obstet Invest; 1996; 42(4):244-8. PubMed ID: 8979096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
    Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
    J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'simple' ovarian cyst: aspirate or operate?
    de Crespigny LC; Robinson HP; Davoren RA; Fortune D
    Br J Obstet Gynaecol; 1989 Sep; 96(9):1035-9. PubMed ID: 2679871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ovarian cysts: strategy and prognosis].
    Querleu D; Parmentier D; Chevallier L
    Contracept Fertil Sex; 1993 Feb; 21(2):167-72. PubMed ID: 7951609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of plasminogen activators in human gingival crevicular fluid.
    Brown JM; Watanabe K; Cohen RL; Chambers DA
    Arch Oral Biol; 1995 Sep; 40(9):839-45. PubMed ID: 8651888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-type plasminogen activator in human aqueous humor.
    Bernatchez SF; Tabatabay C; Belin D
    Invest Ophthalmol Vis Sci; 1992 Aug; 33(9):2687-92. PubMed ID: 1639615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
    Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
    Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic parameters in spermatozoas and seminal plasma.
    Maier U; Kirchheimer JC; Hienert G; Christ G; Binder BR
    J Urol; 1991 Sep; 146(3):906-8. PubMed ID: 1908531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
    Serratì S; Panzardi I; Margheri F; Chillà A; Torre E; Fibbi G; Tonelli P; Del Rosso M
    Oral Dis; 2010 Nov; 16(8):753-9. PubMed ID: 20646237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.